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Metabolic pulse-chase experiments demonstrated that 25-hydroxycholesterol (25-OH), the endogenous activator of the liver X
receptor (LXR), signiﬁcantly reduced the biosynthesis of phosphatidylethanolamine via CDP-ethanolamine (Kennedy) pathway at
thestepcatalyzedbyCTP:phosphoethanolaminecytidylyltransferase(Pcyt2).InthemouseembryonicﬁbroblastsC3H10T1/2,the
LXR synthetic agonist TO901317 lowered Pcyt2 promoter-luciferase activity in a concentration-dependent manner. Furthermore,
25-OH and TO901317 reduced mouse Pcyt2 mRNA and protein levels by 35–60%. The inhibitory eﬀects of oxysterols and
TO901317 on the Pcyt2 promoter function, mRNA and protein expression were conserved in the human breast cancer cells MCF-
7. These studies identify the Pcyt2 gene as a novel target whereby LXR agonists may indirectly modulate inﬂammatory responses
and atherosclerosis.
Copyright © 2008 L. Zhu and M. Bakovic. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Phosphatidylethanolamine (PE) is an essential membrane
phospholipidwithrolesinmultiplecellularprocessesinclud-
ing cellsignaling, membranefusion, celldivision, autophagy,
and apoptosis [1, 2]. Although PE could be synthesized
by phosphatidylserine decarboxylation in mitochondria,
the majority of PE is made de novo in the endoplas-
mic reticulum from ethanolamine and diacylglycerol via
CDP-ethanolamine (Kennedy) pathway [1]. Molecular and
metabolic aspects of the de novo Kennedy pathway and
the role of the major regulatory enzyme Pcyt2 have been
reviewed recently [2].
Liver X receptors (LXRs) are oxysterol-activated nuclear
receptors, which control cholesterol homeostasis by modify-
ing expression of genes involved in cholesterol absorption
and eﬄux from peripheral tissues [3]. LXRs also regulate
genes essential in lipogenesis, glucose metabolism, and
inﬂammation [4]. Regulatory eﬀects of LXRs on phos-
pholipid genes are relatively unknown. Our initial char-
acterization suggest that early growth response protein 1
and nuclear factor κB( N F κB) could be important for the
regulation of the human Pcyt2 gene [2, 5]. Here, we report
that oxysterols, 25-hydroxycholesterol (25-OH) and 22R-
hydroxycholesterol(22R-OH),andtheLXRsyntheticagonist
TO901713 downregulate the CDP-ethanolamine pathway
and inhibit Pcyt2 gene expression by an indirect mechanism
conserved in mouse and human cells.
2.Experimentalprocedures
Cell maintenance and treatment
Mouse embryonic ﬁbroblasts C3H10T1/2 and human breast
cancer cells MCF-7 grown under standard conditions [6,
7] were cultured 40–48 hours in a serum-free media
supplemented with 25-OH (10ng/μL), 22R-OH (10ng/μL),
or TO901713 (0–20μM) and the cells grown in serum-free
media without agonists were used as controls.
14C-ethanolamine radiolabeling and PE mass
C3H10T1/2 cells (106 cells/60mm-dish) were treated with
25-OH for 40 hours, pulse-labeled for 1 hour with 14C-
ethanolamine (0.5μCi/dish), chased with 250μM of “cold”
ethanolamine and collected at diﬀerent time points (0, 0.5,2 Research Letters in Biochemistry
1, 2, and 4 hours). The radio-labeled compounds were
extracted by the Bligh-Dyer method and analyzed by TLC
[6]. Total PE mass was measured using the ﬂuorescent probe
1,6-diphenylhexatriene as we described previously [6].
Pcyt2 promoter-luciferase reporter assays
Transient transfections were performed as initially described
[7]. The transfected cells were incubated for 5 hours in
transfection media and then cultured in the presence or
absence of LXR agonists for additional 48 hours or 15 hours.
Luciferase reporter assays were performed using the dual
luciferase system (Promega, Medison, WI, USA).
Pcyt2 mRNA expression
Total RNA was isolated with Trizol reagent (Invitrogen,
Burlington On, Canada). PCR reactions were performed
with 300ng of single-stranded DNA using Pcyt2 speciﬁc
primers, the forward primer F6 (5 ggagatgtcctctgagtaccg3 )
and the reverse primer R7 (5 ggcaccagccacatagatgac3 ). The
primers produce two fragments of diﬀerent size, 223bp for
Pcyt2α and 170bp for Pcyt2β [8].
Immunoblotting
Cell homogenates were analyzed by western blotting using
anti-Pcyt2α and anti-Pcyt2(α+β) antibodies generated in our
laboratory [6].
Statistical analysis
All measurements are expressed as means ±S.D. from at
least three independent experiments. Data were analyzed
by ANOVA (GraphPad Prism 3.0) and densitometry (Scion
Image, Frederik, Maryland, USA).
3.Results
CDP-ethanolamine (Kennedy) pathway is
downregulated by 25-OH.
The mouse embryonic cells C3H10T1/2 were treated with
10ng/μL of 25-OH oxysterol for 40 hours, radiolabelled with
14C-ethanolamine and chased with an excess of unlabeled
ethanolamine for 0, 0.5, 1, 2, and 4 hours. As shown
in Figure 1(a), the rate of 14C-ethanolamine disappearance
was similar under both conditions, demonstrating that the
ethanolamine kinase step (phosphoethanolamine forma-
tion) was not aﬀected by the treatment. The formed 14C-
phosphoethanolamine decreased from 8847 dpm at time
0 hour to 3246 dpm after 4-hour chase in untreated cells
while in 25-OH treated cells 14C-phosphoethanolamine
disappeared very slowly (Figure 1(b)), suggesting that this
step catalyzed by Pcyt2 was inhibited by the oxysterol
treatment. Consequently, the Pcyt2 product 14C-CDP-
ethanoalmine remained constantly low in 25-OH treated
cells, and the diﬀerence between 14C-CDP-ethanoalmine in
25-OH treated and control cells reached 64% at the end
of the chase (Figure 1(c)). The rates of disappearance of
14C-CDP-ethanoalmine were on the other hand similar,
demonstrating that the last step in the Kennedy pathway
(phosphotransferase step) was not aﬀected by the oxysterol
treatments (Figure 1(c)). The slower formation of CDP-
ethanolamine in 25-OH treated cells was accompanied with
signiﬁcantly reduced rate of 14C-PE synthesis (Figure 1(d)).
Under the same conditions the total PE decreased by ∼32%
in the cells treated with 25-OH (not shown). Taken together,
these data demonstrate for the ﬁrst time that the PE de novo
synthesisviatheKennedypathwaybecamedownregulatedby
25-OH at the step of CDP-ethanolamine formation, which is
catalyzed by Pcyt2.
LXR agonists downregulate mouse Pcyt2 promoter
and gene expression
To establish the mechanism for the 25-OH eﬀect on Pcyt2,
we performed luciferase-reporter assays using the previously
characterized mouse Pcyt2 promoter (−559/+29 bp) [7]. As
shownin Figure 2(a), 25-OH reducedpromoter activity 40%
(P < .05) at the concentration of 10ng/μL after 48 hours
treatments. To test whether the inhibitory eﬀect on Pcyt2
was through the activation of LXR, the C3H10T1/2 cells
were also treated with the speciﬁc LXR agonist TO901317,
and the inhibitory eﬀect of TO901317 on the mouse Pcyt2
promoter was dose-dependent at 0.02–20μM( Figure 2(a)).
The reduction of promoter function was accompanied by
dramatically reduced expression of both Pcyt2α and -β
transcripts (Figure 2(b)). Using speciﬁc antibodies made in
ourlaboratoryfortotalPcyt2(α+β)andforPcyt2αproteins,
we further established that both total Pcyt2 (α + β) and its α
form were signiﬁcantly reduced by the 48 hours treatments
of 25-OH and 1μM TO901317 (Figure 2(c)). These data
demonstrate that 25-OH and LXR speciﬁc ligand TO901317
had similar inhibitory eﬀects on the Pcyt2 gene expression.
When we measured the eﬀects of 25-OH and TO901317 on
Pcyt2 gene expression after 15-hour treatments, the lowering
eﬀects on promoter activities and Pcyt2 protein amounts
were as signiﬁcant as 48 hours treatments (data not shown).
LXR agonists downregulate human Pcyt2 promoter
and gene expression
The eﬀect of LXR agonists on the Pcyt2 gene was also
tested in human cells. The human breast cancer cells
MCF-7 were transiently transfected with the human Pcyt2
promoter luciferase reporter (−590/+56bp) [7]a n dt r e a t e d
with TO901317 (1μM), 25-OH (10ng/μL) or 22R-OH
(10ng/μL). As shown in Figure 3(a), TO901317 reduced
the human Pcyt2 promoter activity by 76% (P < .05),
and oxysterols 25-OH and 22R-OH decreased the luciferase
activity, respectively, by 52% (P < .05) and 63% (P <
.05). In agreement with the eﬀect on the promoter activity,
TO901317, 25-OH and 22R-OH were also able to consider-
ablyreducethetotalPcyt2(α+β)andPcyt2αproteinlevelsin
treated cells relative to untreated MCF-7 cells (Figures 3(b)).Research Letters in Biochemistry 3
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Figure 1: Inhibition of the CDP-ethanolamine pathway by 25-hydroxycholesterol. Mouse cells C3H10T1/2 were treated with 10ng/μL
of 25-OH (ﬁlled triangles), “pulsed” with 14C-Etn for 1 hour and “chased” with an excess of unlabelled ethanolamine as indicated. 14C-
ethanolamine (A), 14C-phosphoethanolamine (B), and 14C-CDP-ethanolamine (C) products were determined from the water phase and the
radio-labeledPE(E)wasquantiﬁedfromtheorganicphase.Untreatedcellsgrowninserum-freemedia(opensquares)wereusedascontrols.
Data shown are from three independent experiments performed in duplicate; (∗) indicates diﬀerences between treatments at P < .05.
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Figure 2: Downregulation of the mouse Pcyt2 gene by 25-hydroxycholesterol and the LXR-speciﬁc agonist TO901317. (a) C3H10T1/2 cells
were cultured in the presence of 25-OH (10ng/μL) or TO901317 (20nM–20μM) for 48 hours. Shown are promoter-luciferase reporter
activities from four independent experiments performed in duplicates. The numerical values represent means ±S.D., with signiﬁcant
diﬀerences indicated as (∗)a tP < .05, (∗∗)a tP < .01 and (∗∗∗)a tP < .001. (b) Pcyt2 mRNAs (α and β) determined in 25-OH (left
panel) and 1μM TO901317 (right panel) treated cells. (c): Western blot showing that 25-OH (left panel) and 1μM TO901317 (right panel)
treatments of C3H10T1/2 cells reduced total (α+β)a n dα Pcyt2 proteins.4 Research Letters in Biochemistry
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Figure 3: LXR agonists attenuate the expression of the human Pcyt2 gene. (a) The human breast cancer cells MCF-7 were transfected with
the human Pcyt2 promoter-luciferase reporter construct and treated with TO901317 (1μM), 25-OH (10ng/μL) or 22(R)-OH (10ng/μL)
for 48 hours. Luciferase activities for untreated and treated cells were performed. Shown are means ±S.D. of at least in four independent
experiments in duplicate, and signiﬁcant diﬀerences are indicated as (∗)a tP < .05, (∗∗)a tP < .01, and (∗∗∗)a tP < .001. (b) Attenuation of
total and α Pcyt2 proteins after various treatments as in (a).
4.Discussion
In this report, we demonstrate for the ﬁrst time that
natural oxysterols and the LXR synthetic agonist T0901317
are inhibitors of the PE de novo synthesis at the step
of CDP-ethanolamine formation by downregulating the
Pcyt2 gene at the transcriptional level. Recently, it has
been demonstrated that oxysterols could also inhibit phos-
phatidylcholine (PC) de novo synthesis by blocking the
phosphorylation of the related enzyme, CTP: phospho-
choline cytidylyltransferase-Pcyt1, in the choline branch
of the Kennedy pathway [9]. That oxysterols and LXR
agonists inhibit PE and PC indicates that they are important
regulators of the membrane biogenesis at the level of the two
major phospholipids.
LXRsarebest-knownfortheirabilitytomodulatecholes-
terol eﬄux by ABCA1 [3] and it is established that reduced
HDL phospholipids (PC and PE) could enhance the ABCA1-
mediated eﬄux and reduce the SR-BI-mediated eﬄux [10].
Therefore, a reduced rate of PE synthesis and for the same
matter reduced PC synthesis by the LXR could potentially
lead to lower phospholipid (PE and PC) availability for
serum lipoproteins, thereby favoring the ABCA1-mediated
cholesteroleﬄuxovertheSR-B1-mediatedcholesteroleﬄux.
In addition, reduced cellular PC and PE, due to inhibition
of Pcyt2 and Pcyt1, could also limit the extent of cholesterol
eﬄux to ApoA1 or HDL since the transport of phospholipids
and cholesterol are linked.
LXRs and their ligands are well-established negative
regulators of the proinﬂammatory genes including COX1/2
and prostaglandin E synthase-1 (PGES-1) [4, 11]. PE and
PE-plasmalogens are the major sources of arachidonic acid,
the principal substrate of the prostanoid inﬂammatory
mediators [12, 13]. COX1 and COX2 convert arachidonic
acid released from PE and PC into prostaglandin H2, which
is a sole substrate for a series of other prostaglandins. Based
on our ﬁndings, the anti-inﬂammatory potency of the LXR
agonists appears to inhibit the phospholipid (PE and PC)
synthesis to reduce the arachidonic acid reservoir pool, in
addition totheirknowneﬀectofsuppressingthearachidonic
acid utilization by COX1/2 and downstream genes.
Anti-inﬂammatory properties of LXR are mostly medi-
ated indirectly by transactivation of other transcription
f a c t o r ss u c ha sN F κB and Ap1(c-Fos/c-Jun) [3, 14]. Our
thorough analysis of the mouse and human Pcyt2 promoter
sequence did not reveal any conserved LXR response ele-
ments [7], suggesting that the observed inhibitory action
of the LXR agonists on the Pcyt2 transcription is also
indirect. We have already established that human Pcyt2
could be regulated by NFκB[ 5], but the mouse form is
not an NFκBt a r g e t[ 7] and the LXR agonists inhibit both
mouse and human promoters. The mouse and human Pcyt2
promoters on the other hand share several putative Ap1
[7] and glucocorticoid receptor (GR) response elements
(data not shown), which could potentially be involved in
the LXR inhibitory action. It is established that the LXR
agonist T0901317 markedly suppresses the GR gene and its
downstream targets involved in hepatic glucose metabolism
and therefore ameliorates diabetic syndrome in db/db mice
[15].
Inconclusion,weestablishedthatoxysterolsandtheLXR
speciﬁcagonistT0901317diminishPcyt2promoterandgene
expression using an indirect mechanism that is conserved
in mouse and human cells. Because LXR agonists inhibiting
PE synthesis may contribute to their eﬀects in cholesterol
homeostasis and inﬂammation, to suppress the de novo PE
synthesis by inhibiting Pcyt2 could be an alternative choice
for developing such therapeutics.
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